248 related articles for article (PubMed ID: 21798265)
1. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
Galimberti ES; Knollmann BC
J Mol Cell Cardiol; 2011 Nov; 51(5):760-8. PubMed ID: 21798265
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
[TBL] [Abstract][Full Text] [Related]
3. Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.
Savio-Galimberti E; Knollmann BC
PLoS One; 2015; 10(6):e0131179. PubMed ID: 26121139
[TBL] [Abstract][Full Text] [Related]
4. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
[TBL] [Abstract][Full Text] [Related]
5. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
Hilliard FA; Steele DS; Laver D; Yang Z; Le Marchand SJ; Chopra N; Piston DW; Huke S; Knollmann BC
J Mol Cell Cardiol; 2010 Feb; 48(2):293-301. PubMed ID: 19835880
[TBL] [Abstract][Full Text] [Related]
6. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
[TBL] [Abstract][Full Text] [Related]
7. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
[TBL] [Abstract][Full Text] [Related]
8. Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.
Maizels L; Huber I; Arbel G; Tijsen AJ; Gepstein A; Khoury A; Gepstein L
Circ Arrhythm Electrophysiol; 2017 Jun; 10(6):. PubMed ID: 28630169
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
[TBL] [Abstract][Full Text] [Related]
10. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG
Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cytosolic and intra-sarcoplasmic reticulum calcium waves by calsequestrin in rat cardiac myocytes.
Kubalova Z; Györke I; Terentyeva R; Viatchenko-Karpinski S; Terentyev D; Williams SC; Györke S
J Physiol; 2004 Dec; 561(Pt 2):515-24. PubMed ID: 15486014
[TBL] [Abstract][Full Text] [Related]
12. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
[TBL] [Abstract][Full Text] [Related]
13. A mutation in calsequestrin, CASQ2D307H, impairs Sarcoplasmic Reticulum Ca2+ handling and causes complex ventricular arrhythmias in mice.
Dirksen WP; Lacombe VA; Chi M; Kalyanasundaram A; Viatchenko-Karpinski S; Terentyev D; Zhou Z; Vedamoorthyrao S; Li N; Chiamvimonvat N; Carnes CA; Franzini-Armstrong C; Györke S; Periasamy M
Cardiovasc Res; 2007 Jul; 75(1):69-78. PubMed ID: 17449018
[TBL] [Abstract][Full Text] [Related]
14. The cardiac ryanodine receptor luminal Ca2+ sensor governs Ca2+ waves, ventricular tachyarrhythmias and cardiac hypertrophy in calsequestrin-null mice.
Zhang J; Chen B; Zhong X; Mi T; Guo A; Zhou Q; Tan Z; Wu G; Chen AW; Fill M; Song LS; Chen SR
Biochem J; 2014 Jul; 461(1):99-106. PubMed ID: 24758151
[TBL] [Abstract][Full Text] [Related]
15. Modest reductions of cardiac calsequestrin increase sarcoplasmic reticulum Ca2+ leak independent of luminal Ca2+ and trigger ventricular arrhythmias in mice.
Chopra N; Kannankeril PJ; Yang T; Hlaing T; Holinstat I; Ettensohn K; Pfeifer K; Akin B; Jones LR; Franzini-Armstrong C; Knollmann BC
Circ Res; 2007 Sep; 101(6):617-26. PubMed ID: 17656677
[TBL] [Abstract][Full Text] [Related]
16. Accentuated vagal antagonism paradoxically increases ryanodine receptor calcium leak in long-term exercised Calsequestrin2 knockout mice.
Ho HT; Thambidorai S; Knollmann BC; Billman GE; Györke S; Kalyanasundaram A
Heart Rhythm; 2018 Mar; 15(3):430-441. PubMed ID: 29030236
[TBL] [Abstract][Full Text] [Related]
17. Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death.
Terentyev D; Nori A; Santoro M; Viatchenko-Karpinski S; Kubalova Z; Gyorke I; Terentyeva R; Vedamoorthyrao S; Blom NA; Valle G; Napolitano C; Williams SC; Volpe P; Priori SG; Gyorke S
Circ Res; 2006 May; 98(9):1151-8. PubMed ID: 16601229
[TBL] [Abstract][Full Text] [Related]
18. Abnormal propagation of calcium waves and ultrastructural remodeling in recessive catecholaminergic polymorphic ventricular tachycardia.
Liu N; Denegri M; Dun W; Boncompagni S; Lodola F; Protasi F; Napolitano C; Boyden PA; Priori SG
Circ Res; 2013 Jul; 113(2):142-52. PubMed ID: 23674379
[TBL] [Abstract][Full Text] [Related]
19. Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.
Kurtzwald-Josefson E; Hochhauser E; Bogachenko K; Harun-Khun S; Katz G; Aravot D; Seidman JG; Seidman CE; Eldar M; Shainberg A; Arad M
Heart Rhythm; 2014 Aug; 11(8):1471-9. PubMed ID: 24768611
[TBL] [Abstract][Full Text] [Related]
20. Functional consequences of stably expressing a mutant calsequestrin (CASQ2D307H) in the CASQ2 null background.
Kalyanasundaram A; Viatchenko-Karpinski S; Belevych AE; Lacombe VA; Hwang HS; Knollmann BC; Gyorke S; Periasamy M
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H253-61. PubMed ID: 21984545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
